Searching for the IDEAL Duration of Adjuvant Endocrine Therapy

被引：0
|
作者：
Yung, Rachel L. [1 ]
Davidson, Nancy E. [1 ]
机构：
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Sch Med, Seattle Canc Care Alliance, 1100 Fairview Ave North, Seattle, WA 98109 USA
来源：
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2018年 / 110卷 / 01期
关键词：
POSITIVE BREAST-CANCER; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; TAMOXIFEN; LETROZOLE;
D O I：
10.1093/jnci/djx143
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：6 / 8
页数：3
相关论文
共 50 条
  • [21] Breast cancer adjuvant endocrine therapy
    Cigler, Tessa
    Goss, Paul E.
    CANCER JOURNAL, 2007, 13 (03): : 148 - 155
  • [22] ADJUVANT THERAPY IN ENDOCRINE DIGESTIVE TUMORS
    RUSZNIEWSKI, P
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1994, 18 (8-9): : 737 - 738
  • [23] Adjuvant Endocrine Therapy for Breast Cancer
    Rao, Ruta D.
    Cobleigh, Melody A.
    ONCOLOGY-NEW YORK, 2012, 26 (06): : 541 - 559
  • [24] Adjuvant endocrine therapy in breast cancer
    Niwinska, Anna
    Litwiniuk, Maria
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2007, 11 (02): : 82 - 88
  • [25] Cardiovascular disease with adjuvant endocrine therapy
    Reactions Weekly, 2018, 1724 (1) : 4 - 4
  • [26] What is the ideal duration of adjuvant therapy for primary breast cancer: are four cycles of cyclophosphamide and doxorubicin enough?
    Shulman L.N.
    Current Oncology Reports, 2001, 3 (6) : 523 - 528
  • [27] Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)
    Van de Velde, C. J. H.
    Blok, E.
    Kranenbarg, E. Meershoek-Klein
    Putter, H.
    Van den Bosch, J.
    Maartense, E.
    Duijm-de Carpentier, M.
    Van Leeuwen-Stok, E.
    Liefers, G. J.
    Nortier, J.
    Rutgers, E.
    Kroep, J.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S9 - S9
  • [28] Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)
    Blok, E. J.
    van de Velde, C. J. H.
    Kranenbarg, E. M. Meershoek-Klein
    Putter, H.
    van den Bosch, J.
    Maartense, E.
    van Leeuwen-Stok, A. E.
    Liefers, G. J.
    Nortier, J. W. R.
    Rutgers, E. J. T.
    Kroep, J. R.
    CANCER RESEARCH, 2017, 77
  • [29] The Optimal Duration of Adjuvant Endocrine Therapy for Early Stage Breast Cancer—With What Drugs and for How Long?
    Stephen R. D. Johnston
    Belinda Yeo
    Current Oncology Reports, 2014, 16
  • [30] Selecting patients for extended adjuvant endocrine therapy
    Dowsett, M.
    BREAST, 2017, 32 : S20 - S20
12345